Objective: Deviations in the apoptotic process have been demonstrated in prostate carcinogenesis. We aimed to evaluate especially the process of extrinsic apoptosis in the spectrum of neoplastic lesions of the prostate epithelium so as to reveal the variations in the apoptotic process.
INTRODUCTION
Dysregulation of apoptotic mechanisms has an important role in carcinogenesis. The blockages in he apoptotic processes may cause genomic instability, accumulation of mutations and finally uncontrolled cell divisions. The extrinsic apoptotic pathway plays a critical role in immunological and non-immunological elimination of the cells exposed to genomic damage. Death and decoy receptors and their regulators have an extraordinary importance. The novel treatment modalities in prostate cancer have come into question with the detection of death and decoy receptors. (1) (2) (3) (4) (5) . another receptor family involved in the extrinsic apoptotic pathway is tumor necrosis factor-related apoptosis-inducing ligand (TraIL) and its receptors (TraIL-r). TraIL is an analogue of FasL. TraIL is expressed on the surface of many normal cells, and up to five types of TraIL-r have been described. among them, TraIL-r1 (Dr4) and TraIL-r2 (Dr5) contain a cytoplasmic death region and transmit apoptotic signals. TraIL-r3 (Dcr1) and TraIL-r4 (Dcr2) block intracellular transmission of signals and hence they are 
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called "decoy receptors" (6) (7) (8) . FLIP (FLICe inhibitor protein) is a protein with amino acid sequences similar to caspase-8 and capsase-10. FLIP competes with them for binding to FaDD (Fas associated death domain) and inhibits Fas-mediated apoptosis at the subreceptor level (9). Some reports are available on FLIP expression in prostate cancers (10).
In this study, our aim was to reveal the probable alterations in extrinsic apoptotic mechanisms in prostatic cancer tissues.
MATERIAL and METHODS
after the approval of the local ethics committee was obtained, we retrospectively reviewed the medical files of cases with benign prostatic hyperplasia (BPH; n=20), high-grade prostatic intraepithelial hyperplasia (HGPIN; n=8) and prostatic adenocarcinoma (PCa; n=82) from the archives of our department. Paraffin blocks and slides of these cases were obtained and reviewed for confirmation of the diagnoses. a total of 110 study participants were diagnosed between 2007 and 2011. Tissue samples of all BPH cases were suprapubic prostatectomy specimens, while those of all HGPIN cases were obtained from trucut biopsy materials. The study material of PCa cases were selected from radical prostatectomy (n=12), transurethral resection (n=2) and tru-cut biopsy (n=68) specimens. PCa cases were classified into three groups according to Gleason total score as the differentiated group (DPCa; score 6), moderately differentiated group (MDPCa; score 7) and poorly differentiated group (PDPCa; score 8-10).
Immunohistochemistry
Immunohistochemical analyses were performed on paraffin sections 4 µm thick. Characteristics of primary antibodies used in the analysis are shown in Table I . The sections were boiled in citrate buffer solution (pH=6) for the epitope retrieval process. Immunohistochemical evaluation for all antibodies was performed on areas that demonstrated the most optimal immunostaining. Cytoplasmic and membranous staining for both glandular and stromal cells was considered as significant ( Figure 1a -D). Intensity and extent of immunostaining for Fas and FasL antibodies were separately scored according to the following scheme Figure 2 ).
Stromal Fas expression showed a significant difference between BPH and PCa. Stromal Fas expression was detected in 45% (9 cases) of the cases in the BPH group (Table II) . Both scores were summarized and cases with a total score of ≥ 4 both for Fas and FasL were accepted as positive. Since HGPIN is a stroma-free lesion, stromal expressions for Fas and FasL were not evaluated in this group. In analyses of FLIP and Dcr1, cytoplasmic staining of glandular epithelial cells was considered to be significant and immunostaining for these two antibodies in more than 5% of glandular areas was accepted as positive. Tonsil tissue was used as the positive control tissue for all antibodies and phosphate buffer solution (PBS) instead of primary antibody as the negative control in the incubation period.
Statistical Analysis
one-way-aNoVa for age was performed while categorized variables were analyzed by chi-square. Fisher's exact test was used if the number of cells with expected frequencies less than five did not exceed 20% of all cells. The independent samples t-test was used for comparison of the mean age between the groups. a p value ≤0.05 was accepted as significant.
RESULTS
The mean age of the study population was 68. while the positivity rate was 1.2% (1 case) in the PCa group. Stromal Fas expression had statistical significance in our study (p<0.001) (Table III, Figure 2 ).
Glandular Fas expression was only seen in 8 cases (9.8%).
The rates of glandular Fas expression were similar in the DPCa, MDPCa and PDPCa groups (11.5%, 8.3% and 9.4%, respectively) (p=0.999) (Table IV, Figure 3 ).
Stromal Fas expression was noted in only one case (1.2%) in the PCa group (p=0.296).
FasL Analysis
Glandular FasL expression could not be evaluated in 2 cases in the PCa group because of technical reasons. Glandular FasL expression showed a statistically significant difference between the groups. eighty percent of the cases of BPH were negative for FasL. Dcr1 positivity was 8.3% in the MDPCa group (Table IV, Figure 5 ).
FLIP Analysis
FLIP expression could be evaluated in only 80 cases in the PCa group. Two cases were excluded due to technical reasons. only 5% of the cases in the BPH group showed positivity for FLIP while the rates of FLIP positivity in the HGPIN and PCa groups were 37.5% and 18.8%, respectively (p=0.102). Stromal and nuclear positivity for FLIP was not seen in any case ( Figure 3 ).
DcR1 Analysis
There was no difference for Dcr1expression between the groups (p=0.999). The highest rate for Dcr1 positivity was 10% among all groups. Stromal and nuclear expressions of Dcr1 were not seen in any group (Table III, Figure 4 ).
The Dcr1 positivity rate was 9.8% (8 cases) in the PCa group. 3.8% of DPCa cases were positive for Dcr1, while 15.6% of PDPCa cases showed Dcr1 positivity (p=0.329). The idea of treatment with activation of apoptosis via these receptors whose presence has been demonstrated in vitro in prostate cancer cell strains has been evaluated as an attractive treatment modality (6) (7) (8) . Since, TNF-α and FasL, have more toxic side effects than TraIL, TraIL is thought to be a safer and more reliable therapeutic agent (31) . on the other hand, nearly 60% of malignancies seen in human beings are resistant to TraIL (32, 33) . Though the mechanism of this resistance is not known for sure, this resistance was suggested to occur by containment of decoy receptors in normal cells in competition with death receptors (34) or the presence of apoptosis-inhibitor molecules like FLIP (24, 35 (38) . These receptors were specific to epithelial cells and they were not observed in stromal cells. Dcr2 receptors were expressed in increasing amounts both in malignant and benign groups. However, expressions of both TraIL and its receptors demonstrated a marked increase in prostate cancer. expression profiles of both TraIL and TraIL-r may have a critical value in the discrimination between benign and malignant tissues and also in the TraIL-mediated gene therapy (38) . Increased Dcr2 receptor expression may complicate
In our study, we also evaluated Fas expression by stromal cells. relative to cases with BPH (45%), a marked loss of stromal Fas expression was seen in the PCa group (1.2 %) (p<0.001). recently, the role of stromal cells in carcinogenesis has been more clearly understood and many researchers have drawn the attention to the role of stromal cells in prostate carcinogenesis and especially their impact on promoting tumoral invasiveness (15) . Increased vulnerability of stromal cells to destructive processes facilitates tumoral invasion. Therefore, an increase in Fas expression by stromal cells can also facilitate tumoral invasion. However, our results seem to contradict these findings. In any event, some data related to prostate carcinogenesis have indicated that loss of stromal Fas expression might have a role in prostate carcinogenesis. Microarray profiles of stromal tissue samples of the prostate glands of the elderly have demonstrated the presence of dysregulations related to some factors derived from stromal cells (16, 17) . alterations in membrane-bound molecules of stromal cells and their secreted molecules can exert important effects on malignant transformation (16) (17) (18) . Loss of stromal Fas confers resistance on stromal cells at least for a while against apoptosis and may maintain some functions that will contribute to tumoral progression. other probable mechanisms related to development of resistance to the apoptotic process despite increased Fas expression in tumoral cells are as follows: production of soluble Fas which neutralizes FasL, overexpression of bcl-2, overexpression of Fas-associated phosphatase 1 which interacts with the suppressive component of Fas, overexpression of FLIP which inhibits Fas-associated apoptosis and mutations in the primary structure of Fas, caspase-8 and caspase-10 (2, 19-28). From these outcomes one can infer that largerscale studies should be performed to reveal the state of Fas expression in benign and malignant prostatic lesions. We have noticed that different scoring systems are used in various studies in the literature. our scoring system was modified from some of these scoring systems. Jiang et al. scored their immunoexpressions according to staining intensity and extensity. Weak, unequivocal-moderate and strong intensities were scored as 1, 2 and 3, respectively, while extensity was evaluated from 5% to 100%. Statistical analysis was performed on the basis of this scoring system. They did not use a cut-off value for positivity (5). Şanlıoğlu et al. scored both of intensity and distribution of immunostaining in their study. Their scoring system was as follows; 0; negative, 1; weak, 2; moderate, 3; strong staining for intensity, while the distribution scale was 0; <10%, 1; 10%-40%, 2; 40%-70% and 3; >70%. a cut-off value for positivity was not used in their study (38) . anees et al. used the values of <10%, 10-30% and >30% for distribution of staining and the values of weak; 1, moderate; 2 and strong; 3 for staining intensity (18) . We have determined our own scoring system by modifying the scoring systems (Table II) and we have used a cut-off value in our study.
as can be inferred from the outcomes of our study, variations in the apoptotic process occur in benign and malignant lesions of the prostatic parenchyma. (18) . anees et al. concluded that the loss of death receptor was associated with higher Gleason score and advanced age (≥ 60 years). although decrease in TraIL-mediated apoptosis with advanced age and higher Gleason scores is accompanied by a decrease in FLIP expression, a decrease in death receptors is the determinative factor. It has been suggested that loss of stromal TraIL expression is seen in malignant transformation, which is also strongly correlated with an unfavorable prognosis (18).
In our study, Dcr1 expression was not seen in the HGPIN group while in other groups Dcr1 expression was very close to each other. Though any intra-group significant difference did not emerge in the PCa group, Dcr1 expression in the DPCa, MDPCa and PDPCa groups was seen at a rate of 3.8 %, 8.3% and 15.6%, respectively (P=0.329). according to our study, rates of Dcr1 positivity increase contrary to decrease in the degree differentiation in prostatic adenocarcinoma. This result may demonstrate -though partially-the potential impact of Dcr1 on the progression facilitating anticipated tumoral invasion, while it might also represent a variation that might prolong the lifespan of the stromal cell so as to contribute to malignant transformation. However, FLIP expression in glandular cells suggests that anti-apoptotic effectiveness is gained during carcinogenesis. another anti-apoptotic mechanism of resistance may be acquired by increased Dcr1 expression observed with decreases in the degree of differentiation in cases with malignancies.
our outcomes indicate that anti-apoptotic mechanisms play important roles in prostate carcinogenesis.
